作 者：Zheng X, Cheng M, Fu B, Fan X, Wang Q, Yu X, Sun R, Tian Z, Wei H.
Abstract：There remains a great need for effective therapies for lung cancer, the majority of which are non-small-cell lung cancers (NSCLC). Here we report the identification of a novel candidate therapeutic target, LunX, as a molecule overexpressed in primary NSCLC and lymph node metastases that is associated with reduced postoperative survival. Functional studies demonstrated that LunX overexpression promoted lung cancer cell migration and proliferation by interactions with the chaperone protein 14-3-3. Conversely, LunX silencing disrupted primary tumor growth, local invasion and metastatic colonization. The finding that LunX was expressed on cell membranes prompted us to generate and characterize LunX antibodies as a candidate therapeutic. Anti-LunX could downregulate LunX and reduce lung cancer cell proliferation and migration in vitro. Administered in vivo to mice bearing lung cancer xenografts, anti-LunX could slow tumor growth and metastasis and improve mouse survival. Together, our work provides a preclinical proof of concept for LunX as a novel candidate target for immunotherapy in lung cancer.
?
版權(quán)與免責(zé)聲明：本網(wǎng)頁的內(nèi)容由收集互聯(lián)網(wǎng)上公開發(fā)布的信息整理獲得。目的在于傳遞信息及分享，并不意味著贊同其觀點(diǎn)或證實其真實性，也不構(gòu)成其他建議。僅提供交流平臺，不為其版權(quán)負(fù)責(zé)。如涉及侵權(quán)，請聯(lián)系我們及時修改或刪除。郵箱：sales@allpeptide.com